Qing Kang1, N Lynn Henry1, Costanza Paoletti1, Hui Jiang2, Pankaj Vats3, Arul M Chinnaiyan4, Daniel F Hayes1, Sofia D Merajver5, James M Rae1, Muneesh Tewari6. 1. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. 2. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 3. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. 4. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA; Department of Urology, University of Michigan, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI, USA; Howard Hughes Medical Institute, Ann Arbor, MI, USA. 5. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 6. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA. Electronic address: mtewari@med.umich.edu.
Abstract
OBJECTIVES: Optimal conditions for blood collection for circulating tumor DNA (ctDNA) are still being developed. Although both Streck and EDTA tubes are commonly used, their ability to stabilize ctDNA as a function of time and temperature post-collection has not been thoroughly studied. Additionally, the potential utility of CellSave tubes (commonly used for circulating tumor cell) for ctDNA measurements has not been studied. DESIGN AND METHODS: Blood was collected into Streck, EDTA, and CellSave tubes from ten patients with metastatic breast cancer enrolled in the MI-ONCOSEQ tumor sequencing program at the University of Michigan and kept either on ice or at room temperature until plasma isolation. Plasma was processed after 2, 6, and 48h post-collection. We used droplet digital PCR (ddPCR) to quantify plasma ctDNA and wild-type DNA for six patients who had tumor tissue mutations represented in commercially available ddPCR assays. RESULTS: ctDNA abundance was similar and stable for up to 6h in all tube types, and there was no effect of storage temperature on the yield for Streck and EDTA tubes. After 48h, however, one out of four patients with detectable ctDNA showed a ~50% decline in ctDNA in the EDTA tube, and three out of six patients showed a 2-3-fold increase in wild-type DNA in the EDTA tube. CONCLUSIONS: Streck, EDTA, and CellSave tubes showed similar performance in preserving ctDNA for up to 6h before plasma isolation. Streck and CellSave tubes more consistently stabilized ctDNA and wild-type DNA at 48h than EDTA tubes. Copyright Â
OBJECTIVES: Optimal conditions for blood collection for circulating tumor DNA (ctDNA) are still being developed. Although both Streck and EDTA tubes are commonly used, their ability to stabilize ctDNA as a function of time and temperature post-collection has not been thoroughly studied. Additionally, the potential utility of CellSave tubes (commonly used for circulating tumor cell) for ctDNA measurements has not been studied. DESIGN AND METHODS: Blood was collected into Streck, EDTA, and CellSave tubes from ten patients with metastatic breast cancer enrolled in the MI-ONCOSEQ tumor sequencing program at the University of Michigan and kept either on ice or at room temperature until plasma isolation. Plasma was processed after 2, 6, and 48h post-collection. We used droplet digital PCR (ddPCR) to quantify plasma ctDNA and wild-type DNA for six patients who had tumor tissue mutations represented in commercially available ddPCR assays. RESULTS: ctDNA abundance was similar and stable for up to 6h in all tube types, and there was no effect of storage temperature on the yield for Streck and EDTA tubes. After 48h, however, one out of four patients with detectable ctDNA showed a ~50% decline in ctDNA in the EDTA tube, and three out of six patients showed a 2-3-fold increase in wild-type DNA in the EDTA tube. CONCLUSIONS: Streck, EDTA, and CellSave tubes showed similar performance in preserving ctDNA for up to 6h before plasma isolation. Streck and CellSave tubes more consistently stabilized ctDNA and wild-type DNA at 48h than EDTA tubes. Copyright Â
Authors: Neerav N Shukla; Juber A Patel; Heather Magnan; Ahmet Zehir; Daoqi You; Jiabin Tang; Fanli Meng; Aliaksandra Samoila; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Ellinor I Peerschke; Agnes Viale; Michael F Berger; Marc Ladanyi Journal: JCO Precis Oncol Date: 2017-05-23
Authors: Matteo Canale; Luigi Pasini; Giuseppe Bronte; Angelo Delmonte; Paola Cravero; Lucio Crinò; Paola Ulivi Journal: Transl Lung Cancer Res Date: 2019-11
Authors: Laure Sorber; Karen Zwaenepoel; Julie Jacobs; Koen De Winne; Kaat Van Casteren; Elien Augustus; Filip Lardon; Hans Prenen; Marc Peeters; Jan Van Meerbeeck; Geert Roeyen; Christian Rolfo; Patrick Pauwels Journal: Mol Diagn Ther Date: 2020-02 Impact factor: 4.074
Authors: Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld Journal: Nat Rev Cancer Date: 2017-02-24 Impact factor: 60.716
Authors: T Stockley; C A Souza; P K Cheema; B Melosky; S Kamel-Reid; M S Tsao; A Spatz; A Karsan Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Matthew J Murray; Hannah L Watson; Dawn Ward; Shivani Bailey; Marta Ferraresso; James C Nicholson; Vincent J Gnanapragasam; Benjamin Thomas; Cinzia G Scarpini; Nicholas Coleman Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-12-18 Impact factor: 4.254